快速标准化的抗结核药物发现治疗效果测定法。
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
机构信息
GlaxoSmithKline, Infectious Diseases Centre of Excellence in Drug Discovery, Diseases of the Developing World, Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2010 May;54(5):2262-4. doi: 10.1128/AAC.01423-09. Epub 2010 Feb 16.
Abstract
Murine models of Mycobacterium tuberculosis infection are essential tools in drug discovery. Here we describe a fast standardized 9-day acute assay intended to measure the efficacy of drugs against M. tuberculosis growing in the lungs of immunocompetent mice. This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin.
摘要
鼠类结核分枝杆菌感染模型是药物发现的重要工具。在这里，我们描述了一种快速标准化的 9 天急性测定法，旨在测量药物对免疫功能正常的小鼠肺部生长的结核分枝杆菌的疗效。该测定法具有高度可重复性，允许高通量，并已使用异烟肼、利福平、乙胺丁醇、吡嗪酰胺、利奈唑胺和莫西沙星进行了药物先导优化的验证。
相似文献
1
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.快速标准化的抗结核药物发现治疗效果测定法。
Antimicrob Agents Chemother. 2010 May;54(5):2262-4. doi: 10.1128/AAC.01423-09. Epub 2010 Feb 16.
2
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.利福喷汀、异烟肼和莫西沙星对结核分枝杆菌的体外抗生素后效应
Antimicrob Agents Chemother. 2004 Jan;48(1):340-3. doi: 10.1128/AAC.48.1.340-343.2004.
3
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.疗程缩短的含莫西沙星方案可使小鼠结核病得到稳定治愈。
Am J Respir Crit Care Med. 2004 Nov 15;170(10):1131-4. doi: 10.1164/rccm.200407-885OC. Epub 2004 Aug 11.
4
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.利福平-硝唑尼特联合用药，而非利福平-异烟肼-吡嗪酰胺-乙胺丁醇，可在中性 pH 缺氧条件下杀死休眠状态的结核分枝杆菌。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00273-19. Print 2019 Jul.
5
Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.莫西沙星和加替沙星在结核分枝杆菌持续感染酸性模型中的研究
J Chemother. 2006 Dec;18(6):617-23. doi: 10.1179/joc.2006.18.6.617.
6
Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.莫西沙星对结核分枝杆菌对数生长期和稳定期培养物的杀菌活性。
J Chemother. 2009 Apr;21(2):127-34. doi: 10.1179/joc.2009.21.2.127.
7
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.加替沙星对结核分枝杆菌的体外和体内活性
Antimicrob Agents Chemother. 2002 Apr;46(4):1022-5. doi: 10.1128/AAC.46.4.1022-1025.2002.
8
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.莫西沙星、左氧氟沙星、加替沙星及利奈唑胺对结核分枝杆菌的体外活性
Int J Antimicrob Agents. 2002 Dec;20(6):464-7. doi: 10.1016/s0924-8579(02)00239-x.
9
Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.在小鼠模型中，恶唑烷酮类药物PNU-100480相对于利奈唑胺具有有前景的抗结核活性。
Antimicrob Agents Chemother. 2009 Apr;53(4):1314-9. doi: 10.1128/AAC.01182-08. Epub 2008 Dec 15.
10
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.苯并噻嗪酮先导化合物 BTZ043 对结核分枝杆菌的体外联合研究。
Antimicrob Agents Chemother. 2012 Nov;56(11):5790-3. doi: 10.1128/AAC.01476-12. Epub 2012 Aug 27.
引用本文的文献
1
Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis.用于治疗结核病的赖氨酰tRNA合成酶抑制剂的设计与开发。
J Med Chem. 2025 Aug 14;68(15):16459-16482. doi: 10.1021/acs.jmedchem.5c01331. Epub 2025 Aug 1.
2
Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon.变革性的结核病治疗：突破、挑战与未来的希望。
Acta Pharm Sin B. 2025 Mar;15(3):1311-1332. doi: 10.1016/j.apsb.2025.01.023. Epub 2025 Jan 31.
3
Identification of a Series Containing a Pentafluorophenyl Moiety That Targets Pks13 to Inhibit Growth of .鉴定出一个含有五氟苯基部分的系列，该系列靶向Pks13以抑制……的生长。
ACS Infect Dis. 2025 Mar 14;11(3):715-726. doi: 10.1021/acsinfecdis.4c00808. Epub 2025 Feb 27.
4
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.直接 InhA 抑制剂在结核分枝杆菌感染小鼠模型中新药物方案中的作用。
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0035724. doi: 10.1128/aac.00357-24. Epub 2024 Sep 30.
5
Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism.利用药物代谢人源化模型加速传染病药物的研发
Proc Natl Acad Sci U S A. 2024 Feb 13;121(7):e2315069121. doi: 10.1073/pnas.2315069121. Epub 2024 Feb 5.
6
Recent developments of imidazo[1,2-]pyridine analogues as antituberculosis agents.咪唑并[1,2 - ]吡啶类似物作为抗结核药物的最新进展。
RSC Med Chem. 2023 Mar 3;14(4):644-657. doi: 10.1039/d3md00019b. eCollection 2023 Apr 26.
7
Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs.赖氨酸 tRNA 合成酶，一种急需的结核分枝杆菌药物靶标。
Nat Commun. 2022 Oct 11;13(1):5992. doi: 10.1038/s41467-022-33736-5.
8
KasA as a drug target: Structure-based inhibitor design.卡萨作为药物靶点：基于结构的抑制剂设计。
Front Cell Infect Microbiol. 2022 Sep 15;12:1008213. doi: 10.3389/fcimb.2022.1008213. eCollection 2022.
9
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective with the Potential To Shorten Tuberculosis Treatment.GSK2556286 是一种新型抗结核候选药物，具有缩短结核病治疗疗程的潜力。
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0013222. doi: 10.1128/aac.00132-22. Epub 2022 May 24.
10
Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target.TAM16（苯并呋喃）优化，一种抑制 Pks13 硫酯酶活性的化合物；针对新型抗结核临床靶点的临床前候选药物的评估。
J Med Chem. 2022 Jan 13;65(1):409-423. doi: 10.1021/acs.jmedchem.1c01586. Epub 2021 Dec 15.
本文引用的文献
1
Animal models of tuberculosis.结核病动物模型。
Eur J Immunol. 2009 Aug;39(8):2011-4. doi: 10.1002/eji.200939542.
2
A dynamic reinfection hypothesis of latent tuberculosis infection.潜伏性结核感染的动态再感染假说。
Infection. 2009 Apr;37(2):80-6. doi: 10.1007/s15010-008-8087-y. Epub 2009 Mar 23.
3
Cell-mediated immune responses in tuberculosis.结核病中的细胞介导免疫反应。
Annu Rev Immunol. 2009;27:393-422. doi: 10.1146/annurev.immunol.021908.132703.
4
Extensively drug-resistant tuberculosis.广泛耐药结核病
Lancet Infect Dis. 2009 Jan;9(1):19-30. doi: 10.1016/S1473-3099(08)70260-3. Epub 2008 Nov 5.
5
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.抗结核药物研发中的药代动力学与药效学
Tuberculosis (Edinb). 2008 Aug;88 Suppl 1:S65-74. doi: 10.1016/S1472-9792(08)70037-4.
6
Preclinical study of new TB drugs and drug combinations in mouse models.新型结核病药物及药物组合在小鼠模型中的临床前研究。
Recent Pat Antiinfect Drug Discov. 2008 Jun;3(2):102-16. doi: 10.2174/157489108784746579.
7
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.OPC-67683，一种硝基二氢咪唑并恶唑衍生物，在体外和小鼠体内对结核病有显著疗效。
PLoS Med. 2006 Nov;3(11):e466. doi: 10.1371/journal.pmed.0030466.
8
Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.新型链阳菌素XRP 2868在小鼠大腿和肺部感染模型中的药效学
Antimicrob Agents Chemother. 2006 Jan;50(1):243-9. doi: 10.1128/AAC.50.1.243-249.2006.
9
Replication dynamics of Mycobacterium tuberculosis in chronically infected mice.结核分枝杆菌在慢性感染小鼠体内的复制动态
Infect Immun. 2005 Jan;73(1):546-51. doi: 10.1128/IAI.73.1.546-551.2005.
10
Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.针对抗结核分枝杆菌新药的快速、简单体内筛选。
Antimicrob Agents Chemother. 2004 Dec;48(12):4550-5. doi: 10.1128/AAC.48.12.4550-4555.2004.
Zotero 插件